

Incretin Mimetics as Emerging Treatments for Type 2 Diabetes

Scott V Joy, Philip T Rodgers, and Ann C Scates

OBJECTIVE: To review the physiology, pharmacology, and clinical efficacy of glucagon-like peptide (GLP-1) and the incretin mimetics exenatide and liraglutide in clinical studies.

DATA SOURCES: Primary literature obtained via MEDLINE (1966–April 2004) and *International Pharmaceutical Abstracts* (1970–April 2004) searches; abstracts obtained from meeting sources and manufacturers.

STUDY SELECTION AND DATA EXTRACTION: All English-language studies and abstracts evaluating GLP-1, exenatide, and liraglutide in the treatment of patients with type 2 diabetes were reviewed. Data from animal studies were also included if human data were not available. Primary and review articles related to the physiology, development, and evaluation of GLP-1s were reviewed.

DATA SYNTHESIS: GLP-1, exenatide (exendin-4, AC2993), and liraglutide (NN2211) are incretin mimetics that have been shown in human studies to be an effective treatment to improve glycemic control in patients with type 2 diabetes. Mechanisms by which these compounds improve glycemic control include enhancing glucose-dependent pancreatic secretion of insulin in response to nutrient intake, inhibiting glucagon secretion, delaying gastric emptying, and promoting early satiety. GLP-1 has been shown to promote pancreatic progenitor cell differentiation and improve β -cell function and lifespan. Reported adverse effects of exenatide and liraglutide include nausea, vomiting, and transient headache, as well as increased risk of hypoglycemia when used with sulfonylureas.

CONCLUSIONS: Clinical studies show that GLP-1, exenatide, and liraglutide improve glycemic control for patients with type 2 diabetes through unique mechanisms not available with current pharmaceutical products. Ongoing Phase III studies will help to further position these compounds as treatment options for patients with type 2 diabetes.

KEY WORDS: exenatide, glucagon-like peptides, incretin mimetics, liraglutide, type 2 diabetes.

Ann Pharmacother 2005;39:110-8.

Published Online, 23 Nov 2004, www.theannals.com, DOI 10.1345/aph.1E245

Currently, 18.2 million Americans have type 2 diabetes, and treatment consists of lifestyle modifications, oral hypoglycemic agents (sulfonylureas, biguanides, acarbose, thiazolidinediones), and/or insulin therapy.¹ Unresponsiveness to oral antihyperglycemic agents is high: after 5–7 years of therapy with sulfonylureas, 50% of these patients will require insulin therapy.² β -Cell dysfunction leads to decreased insulin secretion and resulting hyperglycemia.³ An emerging area of study involves the enteroinsular axis, a process by which peptides (gut hormones, incretin hormones) are secreted by intestinal cells in response to food

intake to affect pancreatic insulin secretion. This article reviews the available data on the naturally occurring incretin hormone glucagon-like peptide (GLP-1) and similar incretin mimetics in Phase III studies (exenatide, liraglutide), with emphasis on the physiology, pharmacokinetics, efficacy, and safety of these compounds and their emerging role in the treatment of patients with type 2 diabetes.

Data Sources

MEDLINE (1966–April 2004) and *International Pharmaceutical Abstracts* searches (1970–April 2004) were conducted for English-language articles using the terms glucagon-like peptides, incretin mimetics, exendin-4, AC2993, exenatide, NN2211, and liraglutide. Articles relevant to the physiology, pharmacology, and efficacy in published clinical trials were reviewed.

Author information provided at the end of the text.

Dr. Joy serves as a consultant for Eli Lilly and Amylin Pharmaceuticals and is a member of the Speaker's Bureau for Pfizer and Wyeth Pharmaceuticals.

Physiology of Incretin Hormones

Incretin hormones are peptides released from cells in the gastrointestinal tract in response to a nutrient stimulus, leading to glucose-dependent insulin release from the pancreas.⁴ GLP-1 is a naturally occurring incretin hormone in humans derived from the proglucagon gene. In mammals, the proglucagon RNA transcript (Figure 1) is translated and processed differently in pancreatic islet cells and intestinal cells.^{5,6} The α cells of the pancreas have prohormone convertase 2 that converts proglucagon into functional glucagon, and intestinal L cells of the jejunum and ileum process proglucagon into GLP-1.⁷⁻⁹ Glucagon is the counterregulatory hormone of insulin, raising plasma levels of glucose in response to insulin-induced hypoglycemia by enhancing glycogenolysis and gluconeogenesis.¹⁰ The 2 forms of GLP-1 secreted after meal ingestion are GLP-1 (7-37)amide and GLP-1 (7-36)amide, which differ by a single amino acid.¹¹ Approximately 80% of circulating active GLP-1 is in the form of GLP-1 (7-36)amide.¹² These 2 hormones have identical half-lives, equal potency, and similar biological activities.¹³ GLP-1 acts by binding to a G-protein-linked receptor expressed on islet β cells.¹⁴

No reports exist of genetic mutations in patients with type 2 diabetes or evidence that patients with maturity-onset diabetes of the young have a genetic linkage to defects of the GLP-1 receptor gene.¹⁵ In patients with type 2 diabetes or impaired glucose tolerance, there are modest but significant reductions in meal-stimulated circulating levels of GLP-1.¹⁶⁻¹⁸ GLP-1 is rapidly secreted by the L cells of the intestine in response to food ingestion in humans, by both neural and hormonal signaling initiated by exposing the proximal gastrointestinal tract to ingested nutrients, as well as by subsequent direct contact of those nutrients as they are exposed to the L cells in the distal jejunum and ileum, particularly in response to a mixed meal or a meal high in fat and complex carbohydrates.^{11,19,20} Release of GLP-1 has been shown to potentiate glucose-dependent insulin secretion by stimulating β -cell growth and differentiation and insulin gene expression.²¹⁻²⁴ GLP-1 has been shown to inhibit β -cell death in human islets cultured in vitro.^{23,25} The mechanism of this

action has been shown in rodent models to involve GLP-1 inducing expression of the homeodomain transcription factor islet duodenum homeobox-1 (IDX-1), a master regulator of pancreas development and β -cell function, inducing progenitor cells found in the pancreatic ducts to develop into β -cells.^{24,26,27} These pancreatic progenitor cells have been isolated from humans, and proof of concept that these cells reside within human pancreatic ducts has been completed.²⁸ These data suggest that GLP-1 can improve β -cell differentiation, increase β -cell mass, and increase β -cell lifespan. Other effects of GLP-1 have been shown to inhibit glucagon secretion, delay gastric emptying, and act through the central nervous system to decrease appetite, increase sensation of satiety, and promote weight loss.²⁹⁻³³

Pharmacology of GLP-1

GLP-1 is inactivated rapidly by dipeptidyl peptidase IV (DPP-IV) in plasma by cleaving the penultimate alanine residue to generate GLP-1 (9-36)amide, with the half-life of intact GLP-1 in vivo <2 minutes.^{34,35} A study of healthy volunteers receiving subcutaneous GLP-1 (7-36) amide showed a dose-related increase of GLP-1 plasma concentrations, and after an intravenous glucose bolus, more than in the basal state, GLP-1 augmented the insulin secretory response and suppressed plasma glucagon.³⁶ A study of healthy patients given an intravenous infusion of GLP-1 during ingestion of a meal showed that GLP-1 increased and augmented the dose-response relationship between glucose concentration and insulin secretion.³⁷ The effect of GLP-1 on glucose control appears to be a function of enhanced, glucose-dependent insulin secretion and not improved peripheral insulin resistance.^{38,39} Comparing acute administration of GLP-1 with a 3-hour infusion of GLP-1 in diabetic and nondiabetic patients showed that both groups had improved insulin secretion, but only the 3-hour infusion led to augmented improvement in first-phase insulin response.⁴⁰ Comparison of 16- and 24-hour infusions of GLP-1 showed that the most efficacious dosing based on nocturnal and fasting plasma glucose levels was in the

24-hour continuous infusion group.⁴¹ Evaluation of GLP-1 (7-36) given by a single buccal tablet showed that therapeutic plasma levels of GLP-1 in healthy humans were achieved, consistent with a relative bioavailability of 7% versus intravenous injection and 47% versus subcutaneous injection.⁴²

The clinical applicability of GLP-1 therefore is limited in humans, as the insulin-secreting effects of GLP-1 are best observed with continuous infusion and that GLP-1 is rapidly degraded by DPP-IV.

Exenatide

Exenatide is a naturally occurring 39-amino acid GLP-1 agonist isolated from the salivary gland venom of the lizard *Heloderma suspectum*.




Figure 1. Proglucagon mRNA transcript. Copyright 2003, The Endocrine Society.⁵ GLP = glucagon-like peptide; GRPP = glicentin-related pancreatic polypeptide; IP = intervening peptide; MPGF = major proglucagon fragment.

tum (Gila monster).⁴³ This peptide has 53% amino acid similarity to mammalian GLP-1, effectively binds to the GLP-1 receptor, and is highly resistant to DPP-IV.⁴⁴ Compared with GLP-1, exenatide has up to 3000-fold greater potency for glucose-lowering in vivo and is a more potent stimulator of glucose-dependent insulin release when given intravenously.⁴⁵⁻⁴⁷ Infusion of exenatide and GLP-1 in animal models has replicated a bell-shaped dose response for both compounds, with exenatide demonstrating a greater maximal effect than GLP-1.⁴⁸ Phase I clinical trials have shown that subcutaneous exenatide was generally well tolerated at doses of ≤ 0.1 $\mu\text{g/kg}$, with nausea and vomiting being dose-limited at 0.3 $\mu\text{g/kg}$, and all exenatide doses increased plasma insulin.⁴⁹ Exenatide suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes β -cell proliferation and neogenesis from precursor cells. Exenatide does not acutely enhance insulin activity in nondiabetic humans and, unlike GLP-1, does not suppress gastric acid secretion.^{39,50-54}

Phase II trials with exenatide in 323 patients with type 2 diabetes identified an optimal glucose-lowering subcutaneous dose range of 0.05–0.2 $\mu\text{g/kg}$.⁵⁵ Transient nausea and vomiting were dose-limiting adverse events, with this nausea mitigated by a dose initiation period of one month at 5 μg twice daily followed by a maintenance dose of 10 μg twice daily.⁵⁶

PHARMACOKINETICS

Exenatide was administered to rats for the purpose of investigating the pharmacokinetics after intravenous, subcutaneous, and intraperitoneal administration, and showed dose-dependent increases in plasma concentration, regardless of administration route.⁵⁷ Exenatide plasma levels exhibited a gradual single-phase decay, occurring 30 minutes after injection of all doses. Clearance of exenatide from plasma was 4–8 mL/min and was primarily cleared via a renal route.

Table 1 describes the pharmacokinetics of exenatide in humans.^{58,59} Exenatide demonstrated first-order pharmacokinetics, with the concentration decreasing in a logarithmic fashion over time and plasma concentrations detectable 6 hours after the injection. The volume of distribution following intravenous infusions to healthy volunteers was 64 ± 7 mL/kg, suggesting that exenatide is not likely to be highly tissue bound. Exenatide is renally cleared, with a documented clearance rate of 1.8 ± 0.2 mL/kg/min.

CLINICAL EFFICACY

Several clinically relevant trials have documented the beneficial effects of exenatide (Table 2^{51,58-61}). A randomized, double-blind, single-dose crossover study in healthy individuals was performed.⁵⁸ Subjects received either exenatide or a placebo infusion of NaCl 0.9%

for a total of 6 hours on day 1, returning in one week to receive another infusion in a double-blind fashion after an 8-hour fast. A standard breakfast was given one hour after start of infusion, and 3 hours later, the subjects were given a free-choice lunch buffet. Food quantities were weighed before and after participants ate lunch, and feelings of fullness were rated.

No patients experienced adverse events from the infusion. In the fasting state in the first hour, fasting plasma glucose levels fell significantly from 81 to 72 mg/dL ($p < 0.005$), with no change in the placebo group. There was no significant change in the 3-hour postprandial glucose level, although the peak postprandial glucose level (glucose excursion) was lower in the exenatide group and gastric emptying time was decreased. Food intake was 19% lower in the exenatide group (208 calories) at the buffet lunch compared with the placebo group, and the effect appeared to carry over to the evening meal. Noting this small decrease in absolute caloric intake, subjects reported no difference in feelings of fullness or nausea.⁵⁸

Protocols to study the effects of exenatide in both a hyperglycemic and fluctuating state of blood glucose concentrations were performed in patients with type 2 diabetes and healthy volunteers.⁶⁰ To reproduce a hyperglycemic state in patients with diabetes, diabetic medications were withheld for 3 days before the study period. A hyperglycemic clamp (continuous glucose infusion) that raised subjects' blood glucose levels by approximately 100 mg/dL from the fasting state for 5 continuous hours was used to measure changes in insulin release. An exenatide infusion was then given for one hour, and a standard meal was given 5.5 hours later. A second protocol allowed the hyperglycemic clamp to be stopped in the third hour to allow plasma glucose to fall to fasting levels, then increased again by 100 mg/dL during the fifth and final hours to determine the level of glucose dependency of exenatide.

The results from the first protocol revealed that insulin release was potentiated during and in the hours following the exenatide infusion. Results from the second protocol showed that, when the fasting state was resumed, insulin levels fell, but when plasma glucose was raised again, plasma insulin levels were potentiated to an even greater de-

Table 1. Pharmacokinetic Parameters of Exenatide

Parameter	Edwards et al. (2001) ⁵⁸	Fineman et al. (2003) ⁵⁹
Dose/route	0.05 pmol/kg/min intravenous	0.08 $\mu\text{g/kg}$ sc
C_{max} ^a	16.4 ± 0.9 pmol/L	163 ± 86 pg/mL (day 1) 159 ± 81 pg/mL (day 28)
$t_{1/2}$ (min) ^a	26 ± 3	202 ± 182 (day 1) 226 ± 170 (day 28)
Cl (mL/min·kg) ^a	1.8 ± 0.2	NR
V_d (mL/kg) ^a	64 ± 7	NR
t_{max} (h)	2–3	NR
C_{max} = peak plasma concentration; Cl = clearance; NR = not reported; $t_{1/2}$ = half-life; t_{max} = time to maximum plasma concentration; V_d = volume of distribution. ^a Mean $\pm$ SEM.		

gree than during the initial phase. The results demonstrated a glucose-dependent insulintropic effect from exenatide, suggesting an amplification of β -cell insulin release when glucose concentrations were above the normal range, but not when glucose concentrations were below or within the normal range.⁶⁰

To evaluate the effect of multiple doses of exenatide over a one-month period, a study of 9 patients with type 2 diabetes (mean age 57 y, mean body mass index [BMI] 33 kg/m², mean glycosylated hemoglobin [HbA_{1c}] 9.1%) not being treated with insulin was performed.⁶¹ Oral diabetic agents were stopped a week prior to the study, and patients were placed on hyperglycemic and hyperinsulinemic euglycemic clamps. Subcutaneous injections of exenatide at an initial dose of 12 pmol/kg were titrated weekly to a maximum of 96 pmol/kg (0.4 μ g/kg). Exenatide was continued for one month, and patients were instructed to monitor their blood glucose levels at least 8 times a day (before and 1 hour after every meal as well as before and after the exenatide injection). Hyperglycemic and hyperinsulinemic euglycemic clamps were repeated at the end of the study.

Results showed that exenatide reduced HbA_{1c} (9.1% vs 8.3%; $p = 0.009$) and lowered glucose one hour after breakfast ($p < 0.0001$) after twice-daily dosing. No difference was noted in glucose response, plasma insulin levels, or glucagon after a month of exenatide compared with before treatment. However, C-peptide levels were significantly higher during the clamp. A favorable response to

adipose tissue sensitivity to insulin was noted, with nonesterified free fatty acid levels higher after exenatide treatment, and no desensitization to the effects of exenatide over the course of the month were observed.⁶¹

Kolterman et al.⁵¹ published a trial that included 2 sub-studies of exenatide use in patients with type 2 diabetes. The aim of study A was to investigate postprandial glucose response, and study B evaluated the effect on fasting plasma glucose levels. In study A, patients with type 2 diabetes (mean age 56 y, mean BMI 29 kg/m², mean HbA_{1c} $\leq$ 12%, fasting plasma glucose $<$ 260 mg/dL) were divided into groups based on their baseline diabetes therapy: (1) diet management alone, (2) oral therapy with HbA_{1c} $<$ 8%, (3) oral therapy with HbA_{1c} 8–12%, or (4) insulin treated. Subjects were randomly given a dose of exenatide 0.1 μ g/kg or placebo subcutaneously twice a day for 5 days, then switched to the other arm after a 2- to 3-day washout period. Patients were given a standardized liquid breakfast 10 minutes after their morning injection, and postprandial information was recorded. A dose of acetaminophen was given to measure gastric emptying.

The authors observed that postprandial glucose levels were significantly lower over the 5 hours after the standard meal for the exenatide group versus placebo, with no difference between day 1 or day 5, nor between any of the predefined patient groups. Plasma glucose levels in the exenatide group were lower in the hours after the meal (from 160 to 126 mg/dL at 3 h), compared with placebo where it

Table 2. Summary of Clinical Trials with Exenatide and Liraglutide

Reference	Pts.	Treatment	Dose	Significant Clinical Response
Exenatide				
Edwards et al. (2001) ⁵⁸	healthy non-diabetics (n = 8)	single 6-h infusion	0.05 pmol/kg/min	lower FBG, lower glucose excursion, reduced food intake
Egan et al. (2002) ⁶⁰				
protocol 1	healthy non-diabetics (n = 7)	single 1-h infusion	0.15–0.59 pmol/kg/min	overall insulin release potentiated after infusion
protocol 2	non-insulin-treated type 2 diabetics (n = 7)	single 1-h infusion	0.15–0.59 pmol/kg/min	insulin release amplified when glucose levels above normal
Egan et al. (2003) ⁶¹	non-insulin-treated type 2 diabetics (n = 9)	1 mo, once or twice daily sc injections	12–96 pmol/kg (0.05–0.4 μ g/kg)	lower HbA _{1c} , FPG, and 1-h PPPG; elevated C-peptide, NEFA levels
Kolterman et al. (2003) ⁵¹				
study A	type 2 diabetics (n = 24)	5 days, twice-daily sc injections	0.1 μ g/kg	lower PPPG, postprandial insulin, delayed gastric emptying
study B	type 2 diabetics (n = 13)	single-dose sc injections	0.05, 0.1, 0.2 μ g/kg	lower FPG, increased insulin levels at 3 h, no clinical differences among the 3 doses in glycemic control
Fineman et al. (2003) ⁵⁹	type 2 diabetics (n = 109)	28 days, 2 or 3 times a day sc injections	0.08 μ g/kg	lower fructosamine, HbA _{1c} , PPPG; increased β -cell function
Liraglutide				
Juhl et al. (2002) ⁶⁶	type 2 diabetics (n = 11)	single sc dose	10 μ g/kg	lower FPG and premeal glucose; lower glucose exposure and excursion; increased insulin levels and delayed gastric emptying
Chang et al. (2003) ⁶⁵	type 2 diabetics (n = 10)	single sc dose	7.5 μ g/kg	increased insulin levels in response to elevated glucose levels

FPG = fasting plasma glucose; HbA_{1c} = glycosylated hemoglobin; NEFA = nonesterified free fatty acid; PPPG = postprandial plasma glucose.

increased (from 170 to 289 mg/dL). Use of postprandial insulin was significantly lower in the exenatide group, with similar results found on days 1 and 5. Glucagon levels did not change from baseline in the exenatide group, but increased in the placebo group after the meal. Gastric emptying was delayed, as measured by postprandial plasma acetaminophen concentrations, which showed much reduced levels for the first 3 hours; peak concentrations at 5 hours were not different.⁵¹

Study B was a randomized, double-blind, placebo-controlled, 4-period crossover trial of patients with type 2 diabetes receiving only oral therapy for diabetes (mean age 49 y, mean BMI 33 kg/m²).⁵¹ In 4 random sequences, subjects were given subcutaneous placebo or exenatide 0.05, 0.1, or 0.2 µg/kg as single doses each evening before a study day. All doses of exenatide reduced fasting plasma glucose significantly compared with placebo; no dose was found to be significantly better. The nadir of the plasma glucose occurred 3 hours after the dose given the night before, although it was still significantly lower at 8 hours. A dose-dependent rise in plasma insulin levels for the first 3 hours after the dose was observed, and by 8 hours, insulin levels were similar to those of placebo. No differences in glucagon levels were noted compared with placebo, although the authors noted a trend toward suppression in the exenatide groups. Mild adverse effects included headache, nausea, and vomiting; no subjects withdrew because of adverse effects.

A multicenter, triple-blind, randomized, parallel, placebo-controlled study examining the effects of exenatide in combination with existing oral drug therapy for diabetes was performed.⁵⁹ Patients (mean age 52 y, mean HbA_{1c} 9.2%, mean BMI 33 kg/m²) were taking either a sulfonylurea, metformin, or both at stable doses for at least 6 months prior to enrolling in the study and continued these medications throughout the study. Patients were assigned to 1 of 4 groups for a treatment period of 28 days: placebo or exenatide 0.08 µg/kg at breakfast and supper, or at breakfast and bedtime, or 3 times a day (all pts. received subcutaneous injections 3 times a day, with placebo used as needed to maintain assigned group). Measurements of fructosamine, HbA_{1c}, body weight, lipids, and other parameters were performed at baseline and day 28; fasting and postprandial glucose (after a standardized meal) were obtained at these times and also on day 14.

The results showed that fructosamine was significantly reduced in the exenatide groups compared with placebo ($p < 0.004$). HbA_{1c} was also significantly reduced compared with placebo, with an overall mean reduction of 0.9% across the treatment groups ($p < 0.006$). β-Cell function, as calculated by the homeostasis model analysis, was 50–100% greater in the exenatide groups compared with placebo ($p < 0.05$). Postprandial glucose levels were significantly lower in the exenatide groups versus placebo, observed on the first day of therapy and maintained until day 28 ($p < 0.004$). Fasting plasma glucose was not significantly different compared with placebo at day 28. There were no differences between the various exenatide regimens for any of these parameters, and no changes in body weight, lipids, vital signs, hemato-

logic parameters, or cortisol were observed. About 20% of patients treated with exenatide developed low-titer antibodies with no effect on therapeutic results. Mild to moderate nausea developed in 31% of exenatide patients, most occurring in the initial days of therapy; only 4 patients withdrew from the study due to nausea, and only 13% had persistent nausea for the entire treatment period. Fifteen percent of patients experienced hypoglycemia, occurring only in those taking concurrent sulfonylurea therapy with exenatide.⁵⁹

Liraglutide

Liraglutide (NN2211) is a synthetic acylated derivative of GLP-1 that has agonist activity at GLP-1 receptors being developed for once-daily subcutaneous injection. The prolonged effects of liraglutide are obtained by attaching a fatty acid molecule at one position of the GLP-1 molecule that allows for binding to albumin and a slow release from the reservoir. Subcutaneous dosing of liraglutide has been shown in animal models to reduce food intake and body weight, increase insulin secretion, inhibit glucagon secretion, decrease gastric emptying, reduce blood glucose in a dose-dependent manner, and increase the proportion of pancreatic β-cells in mice.⁶²⁻⁶⁴

Single doses of liraglutide administered to human subjects with type 2 diabetes have shown significant increases in insulin and C-peptide levels in a glucose-dependent manner compared with placebo, and liraglutide administered at bedtime significantly lowered fasting and postprandial glucose, suppressed glucagon secretion, and delayed gastric emptying.^{65,66}

PHARMACOKINETICS

Studies with healthy men to investigate the pharmacokinetics, safety, tolerability, and pharmacodynamics of liraglutide when administered in single doses by the subcutaneous and intravenous routes were performed.^{66,67} Table 3 documents the pharmacokinetic results from subjects administered 5 µg/kg intravenously and 10 µg/kg subcutaneously. A subcutaneous dose of 10 µg/kg administered at bedtime had a half-life of 10 hours and a time to maximum concentration of 12 hours, suggesting that bedtime dosing should provide for maximum plasma concentrations to occur during the day.⁶⁶ The absolute bioavailability of liraglutide was determined to be 55%.⁶⁷

A single-center, randomized, double-blind, placebo-controlled, parallel-group dose-escalation study in healthy men ($n = 30$) was conducted, with data analyzed on day 1 to determine single-dose kinetics and after days 5–11 to determine multiple-dose kinetics. Pharmacokinetic data for subjects administered liraglutide 10 µg/kg are summarized in Table 3.⁶⁸

CLINICAL EFFICACY

Published clinical studies of liraglutide are summarized in Table 2. A randomized, double-blind, crossover trial

comparing placebo with a single dose of liraglutide for patients with type 2 diabetes (mean age 59 y, BMI 29 kg/m², HbA_{1c} 6.5%) previously treated with either diet, sulfonylureas, or metformin was performed.⁶⁶ Diabetic drug therapy was withheld for 2 days before the start of the trial, and then placebo or liraglutide was given subcutaneously at a dose of 10 µg/kg at 2200, with fasting blood samples obtained the following morning. At 900, an accepted standard process to measure responsiveness of β-cells to release insulin was performed, known as a pulsatile glucose infusion, which is a one-minute glucose infusion given every 10 minutes for 90 minutes. Subjects ate a standard meal at 1130, and blood samples were obtained for 4 hours after the meal. The ability of the patients to finish the meal and adverse effects that developed were noted.

The results showed that fasting plasma glucose was lower (124 vs 145 mg/dL; $p < 0.05$) with liraglutide versus placebo. After the meal, overall glucose exposure (as measured by AUC) was reduced 23% in the liraglutide group, and glucose excursion was 27% lower; no hypoglycemia was reported. Fasting insulin secretion and peak insulin values after the meal were increased in the liraglutide group, gastric emptying was significantly delayed, and no effect was observed on insulin sensitivity. No changes in fasting glucagon were noted, but postprandial glucagon was suppressed. Two patients experienced nausea after treatment with liraglutide, with one episode severe enough to limit meal consumption.⁶⁶

A randomized, double-blind, crossover study to measure the effects of a single dose of liraglutide on β-cell sensitivity to an increasing dose of glucose via a glucose infusion in patients with type 2 diabetes (mean age 62 y, mean BMI 30 kg/m², mean HbA_{1c} 6.5%) was performed.⁶⁵ For comparison, 10 non-diabetic patients were placed only on the glucose infusion described below. Diabetic drug therapy was stopped one day to one week prior to study initiation. Diabetic patients were given a subcutaneous injection of liraglutide 7.5 µg/kg or placebo at 2300 the night before the study day. The subjects also received a continuous insulin infusion of 0.5–5 units/h to ensure baseline fasting glucose levels were controlled and similar between subjects the next morning. The next day, a graded glucose in-

fusion was started. For the first 3 hours, glucose was given to raise plasma glucose levels from 90 to about 215 mg/dL, with intravenous insulin started to lower the plasma glucose to 90 mg/dL. A dextrose infusion was then started to increase the plasma glucose level again to 215 mg/dL over the next 3 hours.

The results showed that glucose levels throughout the study were very similar between all groups (treatment, placebo, healthy subjects) as would be expected since the goal was to keep glucose levels the same throughout the study. However, plasma insulin C-peptide levels, which were similar in the fasting state, were significantly higher in the treatment group compared with placebo ($p < 0.0001$). The insulin secretion rate was significantly greater with liraglutide than placebo ($p < 0.0001$) and was similar to that of the healthy subjects. The effect was observed as early as 40–60 minutes into the glucose infusion, and β-cell sensitivity was estimated to have increased 70% with the liraglutide treatment. All subjects completed the trial, no hypoglycemia was noted, and adverse effects were mild diarrhea and headache.⁶⁵

Drug Interactions

Hypoglycemia was more common when exenatide was used in combination with a sulfonylurea. Care must be taken to closely monitor blood glucose levels should these newer agents be used as add-on therapy with sulfonylureas. Patients should be educated and instructed to monitor for signs of hypoglycemia and to self-monitor blood glucose levels with the use of these incretin mimetics as monotherapy or if used in combination with other hyperglycemic agents.

Cost

Cost information is not available for exenatide or liraglutide since these agents are both investigational. Pharmacoeconomic issues that will impact their utilization include the individual cost of each therapy, whether the use of other antidiabetic agents can be reduced, whether reductions in hospital admissions are possible, and whether diabetic complication can be prevented, minimized, or eliminated.

Summary

Emerging evidence of the role of the enteroinsular axis in glucose homeostasis has led to the development of 2 clinically appealing incretin mimetics, exenatide and liraglutide. These compounds have been shown to improve glucose control in patients with type 2 diabetes, with favorable effects on insulin secretion, β-cell function, and gastric emptying. Longer-term studies currently ongoing will further position these peptides as clinical options to be used as monotherapy or in combination with biguanides or sulfonylureas to improve glycemic control for patients with type 2 diabetes.

Table 3. Pharmacokinetic Parameters of Liraglutide				
Parameter	Elbrond et al. (2002) ^{67,a}		Agero et al. (2002) ^{68,b}	
	10 µg/kg sc	5 µg/kg iv	(day 1)	(day 11)
Dose/route	10 µg/kg sc	5 µg/kg iv	10 µg/kg sc	10 µg/kg sc
C _{max} (nmol/L)	7.9 ± 2.7	NR	8 ± 1	11 ± 2
t _{1/2} (h)	14	8	12.8	12.8
AUC (h·nmol/L)	235 ± 33	216 ± 43	246 ± 43	351 ± 60
Cl (mL/min·kg)	NR	0.10 ± 0.02	0.16 ± 0.03	NR
V _d (L/kg)	NR	0.07 ± 0.01	0.17 ± 0.03	NR
t _{max} (h)	12 ± 6	NR	11 ± 1	10 ± 2

C_{max} = peak plasma concentration; Cl = clearance; NR = not reported; t_{1/2} = half-life; t_{max} = time to maximum plasma concentration; V_d = volume of distribution.
^aMean ± SD.
^bMean ± SEM.

Scott V Joy MD CDE FACP, Assistant Professor of Clinical Medicine, Duke University Medical Center, Durham, NC

Philip T Rodgers PharmD BCPS CDE CPP, Clinical Assistant Professor, University of North Carolina; Clinical Pharmacist, Duke University Health System

Ann C Scates PharmD, Clinical Pharmacist and Drug Information Specialist, Duke University Hospital

Reprints: Dr. Joy, Duke University Medical Center, 3024 Pickett Rd., Durham, NC 27705-0493, fax 919/419-5842, joy00002@mc.duke.edu

References

- Centers for Disease Control and Prevention. Diabetes public health resources. cdc.gov/diabetes/pubs/estimates.htm (accessed 2004 May 12).
- Scheen AJ, Lefebvre PJ. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. *Diabetes Res Clin Pract* 1989;6(suppl):S33-43.
- Polonsky KS. The β cell in diabetes: from molecular genetics to clinical research. *Diabetes* 1995;44:705-17.
- Creutzfeldt W, Ebert R. New developments in the incretin concept today. *Diabetologia* 1985;28:565-73.
- Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. *Mol Endocrinol* 2003;17:161-71.
- Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. *J Biol Chem* 1986;261:11880-9.
- Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, Orci L, et al. Severe defect in proglucagon processing in islet α -cells of prohormone convertase 2 null mice. *J Biol Chem* 2001;276:27197-202.
- Rouille Y, Westermark G, Martin S, Steiner D. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha Tc1-6 cells. *Proc Natl Acad Sci USA* 1994;91:3242-6.
- Rouille Y, Kantengwa S, Imringer J, Halban P. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. *J Biol Chem* 1997;272:32810-6.
- Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. *Am J Physiol Endocrinol Metab* 2003;284:E671-8.
- Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. *Diabetes Care* 2003;26:2929-40.
- Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. *Diabetes* 1994;43:535-9.
- Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagon-like peptide 1(7-36)amide and glucagon-like peptide 1(7-37) in healthy subjects are indistinguishable. *Diabetes* 1993;42:658-61.
- Thorens B, Porrer A, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor demonstrating that exendin 4 is an agonist and exendin-(9-39) an antagonist of the receptor. *Diabetes* 1993;42:1678-82.
- Zhang Y, Cook JT, Hattersley AT, Firth R, Saker PJ, Warren-Perry M, et al. Non-linkage of the glucagon-like peptide-1 receptor gene with maturity onset diabetes of the young. *Diabetologia* 1994;37:721-4.
- Viltsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. *Diabetes* 2001;50:609-13.
- Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, Ognibene C, et al. Evidence for early impairment of glucagon-like peptide 1 induced insulin secretion in human type 2 (non-insulin dependent) diabetes. *Horm Metab Res* 2002;34:150-4.
- Viltsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide 1 in obese type 2 diabetic patients and healthy subjects. *J Clin Endocrinol Metab* 2003;88:220-4.
- Hermann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide 1 and glucose dependent insulin releasing polypeptide plasma levels in response to nutrients. *Digestion* 1995;56:117-26.
- Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1(7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. *J Endocrinol* 1993;138:159-66.
- Kreymann B, Ghatel MA, Williams G, Bloom SR. Glucagon-like peptide-1 (7-36): a physiological incretin in man. *Lancet* 1987;2:1300-4.
- Habener JF. Glucagonlike peptide-1 agonist stimulation of β cell growth and differentiation. *Curr Opin Endocrinol Diabetes* 2001;8:74-81.
- Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *Proc Natl Acad Sci USA* 1987;84:3434-8.
- Kjemis LL, Holst JJ, Valund A, Madsbad S. The influence of GLP-1 on glucose stimulated insulin secretion: effects on β -cell sensitivity in type 2 and nondiabetic subjects. *Diabetes* 2003;52:380-6.
- Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noshmeh H, et al. Glucagon like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 2003;141:5149-58.
- Sharma A, Zangen DH, Reitz P, Taneja M, Lissauer ME, Miller CP, et al. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. *Diabetes* 1999;48:507-13.
- Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. *Natl Med* 2000;6:278-82.
- Bonner-Weir S, Taneja M, Weir GC, Tatarkiewicz K, Song KH, Sharma A, et al. In vitro cultivation of human islets from expanded ductal tissue. *Proc Natl Acad Sci USA* 2000;97:7999-8004.
- Matsuyama T, Komatsu R, Namba M, Watanabe N, Itoh H, Tarui S. Glucagon like peptide -1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. *Diabetes Res Clin Pract* 1988;5:281-4.
- Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. *Dig Dis Sci* 1993;38:665-73.
- Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. *Am J Clin Nutr* 1998;68:525-30.
- Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, et al. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. *Obes Res* 1998;6:147-56.
- Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. *Endocrinology* 2000;141:1936-41.
- Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. *Endocrinology* 1995;136:3585-96.
- Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. *Eur J Biochem* 1993;214:829-35.
- Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. *Diabetologia* 1995;38:720-5.
- Ahren B, Holst JJ, Mari A. Characterization of GLP-1 effects on β cell function after meal ingestion in humans. *Diabetes Care* 2003;26:2860-4.
- Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KGMM, et al. GLP-1 does not acutely affect insulin sensitivity in healthy men. *Diabetologia* 1996;39:1227-32.
- Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1(7,36)-amide on insulin action in non-diabetic humans. *Diabetologia* 2002;45:1410-5.
- Quddusi S, Vahl TP, Hanson K, Pigeon RL, D'Alessio DA. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first and second phase insulin secretion in diabetic and nondiabetic humans. *Diabetes Care* 2003;26:791-8.
- Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. *Diabetes Care* 2001;24:1416-21.
- Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potential therapeutic levels of glucagon-like peptide 1 achieved in humans by a buccal tablet. *Diabetes Care* 1996;19:843-8.
- Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin 4, an exendin 3 analogue from *Heloderma suspectum* venom. *J Biol Chem* 1992;267:7402-5.
- Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin-4 in the lizard. *J Biol Chem* 1997;272:4108-15.

45. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese (ob/ob, db/db) diabetic mice, diabetic Fatty Zucker rats and diabetic rhesus monkeys (*Macaca mulatto*). *Diabetes* 1999;48:1026-34.
46. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. *Diabetologia* 1999;42:45-50.
47. Young AA, Bronislava RG, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose lowering and insulin-sensitizing actions of exendin-4. *Diabetes* 1999;48:1026-34.
48. Parkes DG, Pittner R, Jodka C, Smith P, Yound A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. *Metabolism* 2001;50:583-9.
49. Kolterman O, Young G, Parker J, Amin D, Prickett K. Stimulation of endogenous insulin secretion by subcutaneous AC-2993 (synthetic exendin-4) in healthy overnight fasted volunteers (abstract). *Diabetes* 1999;48(suppl 1):A199.
50. Gedulin B, Jodka C, Hoyt J. Exendin-4 (AC-2993) decreases glucagon secretion during hyperglycemic clamps in diabetic fatty Zucker rats (abstract). *Diabetes* 1999;48:A199.
51. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metab* 2003;88:3082-9.
52. Gedulin B, Lawler R, Jodka C, Young A. Amylin inhibits pentagastrin-stimulated gastric acid secretion: comparison with glucagon-like peptide-1 and exendin-4 (abstract). *Diabetes* 1997;46:188A.
53. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. *Endocrinology* 2000;141:1936-41.
54. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both B cell replication and neogenesis, resulting in increased B cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 1999;48:2270-6.
55. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. *Current Opin Investig Drugs* 2003;4:401-5.
56. Fineman M, Shen L, Smitzi J, Aisporna A, Bicsak T, Taylor K, et al. Unique study design: evaluation of the effect of dose titration on dose-limiting nausea (abstract). *Clin Pharmacol Ther* 2002;71:P19.
57. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. *Drug Dev Res* 2001;53:260-7.
58. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. *Am J Physiol Endocrinol Metab* 2001;281:E155-61.
59. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. *Diabetes Care* 2003;26:2370-7.
60. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. *J Clin Endocrinol Metab* 2002;87:1282-90.
61. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. *Am J Physiol Endocrinol Metab* 2003;284:1072-9.
62. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. *Diabetes* 2001;50:2530-9.
63. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. *Eur J Pharmacol* 2002;451:217-25.
64. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β -cell mass in diabetic mice. *Am J Physiol Endo Metab* 2002;283:E745-52.
65. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, et al. The GLP-1 derivative NN2211 restores β -cell sensitivity to glucose in type 2 diabetic patients after a single dose. *Diabetes* 2003;52:1786-91.
66. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. *Diabetes* 2002;51:424-9.
67. Elbrond B, Jakobsen G, Larsen H, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. *Diabetes Care* 2002;25:1398-404.
68. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. *Diabetologia* 2002;45:195-202.

EXTRACTO

OBJETIVO: Análisis de la fisiología, farmacología y eficacia, clínica del péptido análogo del glucagón (GLP-1) y de los miméticos de la incretina, exenatida, y liraglutida en estudios clínicos.

FUENTES DE INFORMACIÓN: Fuentes primarias obtenidas a través de MEDLINE y de los motores de búsqueda de *International Pharmaceutical Abstract* y extractos obtenidos a partir de congresos y fabricantes

SELECCIÓN DE FUENTES Y MÉTODO DE OBTENCIÓN DE LA INFORMACIÓN: Se analizaron todos los estudios y extractos en lengua inglesa que evalúan el péptido análogo del glucagón, la exenatida, y la liraglutida en el tratamiento de pacientes con diabetes de tipo 2. También se introdujeron datos obtenidos de estudios con animales si no había datos disponibles de estudios en humanos. Se analizaron artículos primarios y de revisión relacionados con la fisiología, el desarrollo, y la evaluación de péptidos análogos del glucagón.

SÍNTESIS DE DATOS: En estudios con humanos se ha demostrado que el GLP-1, la exenatida (exenatide-4, AC2993), y la liraglutida (NN2211) son miméticos de la incretina que constituyen un tratamiento eficaz para mejorar el control glucémico en pacientes con diabetes de tipo 2. Estos compuestos mejoran el control glucémico mediante un incremento de la secreción pancreática de insulina dependiente de glucosa en respuesta a la ingestión de nutrientes, la inhibición de la secreción de glucagón, el retraso del vaciado gástrico, y la producción de saciedad temprana. Se ha demostrado que el GLP-1 promueve la diferenciación celular de las células germinales pancreáticas y mejora la función y la longevidad de las células β . Los efectos indeseables notificados para exenatida y liraglutida son náuseas, vómitos, cefaleas transitorias, y mayor riesgo de hipoglucemia cuando se usan de forma conjunta con sulfonilureas.

CONCLUSIONES: Los estudios clínicos indican que el GLP-1, la exenatida, y la liraglutida mejoran el control glucémico en pacientes con diabetes de tipo 2 a través de mecanismos singulares distintos a los obtenidos con los fármacos actuales. Los estudios de Fase III que están en curso ayudarán a considerar estos compuestos como opciones terapéuticas para pacientes con diabetes de tipo 2.

Violeta Lopez Sanchez

RÉSUMÉ

OBJECTIF: Revoir la physiologie, la pharmacologie, et l'efficacité clinique du peptide analogue du glucagon (PAG-1) et des substances qui miment l'action des hormones incrétines, l'exenatide, et le liraglutide, dans les études cliniques.

REVUE DE LITTÉRATURE: Littérature primaire obtenue grâce à des recherches via MEDLINE et via l'*International Pharmaceutical Abstracts*; résumés obtenus des manufacturiers et lors de conférences.

SÉLECTION DES ÉTUDES ET SÉLECTION DE L'INFORMATION: Toutes les études de langue anglaise et les résumés évaluant le PAG, l'exénatide, et le liraglutide dans le traitement des patients souffrant de diabète de type 2 ont été révisées. Si des données chez les humains n'étaient pas disponibles, les données tirées des études réalisées chez les animaux étaient utilisées. Les articles primaires et les articles de revue concernant la physiologie, le développement, et l'évaluation des peptides analogues du glucagon ont été révisés.

RÉSUMÉ: Le PAG-1, l'exanétide (exendin-4, AC2993), et le liraglutide (NN2211) sont des substances qui miment l'action des hormones incrétines. Dans les études cliniques, ces substances ont été démontrées efficaces pour améliorer le contrôle de la glycémie chez les patients souffrant de diabète de type 2. Les mécanismes par lesquels ces

composés améliorent le contrôle de la glycémie incluent l'augmentation de la sécrétion glucose dépendante de l'insuline par le pancréas en réponse à l'ingestion de nutriments, l'inhibition de la sécrétion du glucagon, le retardement de la vidange gastrique, et l'atteinte rapide de la satiété. Il a été démontré que le PAG-1 favorise la différenciation des cellules souches pancréatiques et améliore la fonction des cellules bêta et leur durée de vie. Parmi les effets indésirables de l'exénatide et du liraglutide, on retrouve les nausées, les vomissements, les céphalées transitoires de même qu'une augmentation du risque d'hypoglycémie lorsqu'utilisés en association avec les sulfonylurées.

CONCLUSIONS: Les études cliniques démontrent que le PAG-1, l'exénatide, et le liraglutide améliorent le contrôle de la glycémie chez les patients souffrant de diabète de type 2 par des mécanismes d'action uniques non existants parmi les produits pharmaceutiques actuels. Les études de Phase III en cours aideront à positionner ces produits parmi les options thérapeutiques pour traiter les patients souffrant de diabète de type 2.

Marie Larouche